BR112013025420A2 - medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento - Google Patents

medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento

Info

Publication number
BR112013025420A2
BR112013025420A2 BR112013025420A BR112013025420A BR112013025420A2 BR 112013025420 A2 BR112013025420 A2 BR 112013025420A2 BR 112013025420 A BR112013025420 A BR 112013025420A BR 112013025420 A BR112013025420 A BR 112013025420A BR 112013025420 A2 BR112013025420 A2 BR 112013025420A2
Authority
BR
Brazil
Prior art keywords
medicament
pharmaceutical composition
compound
medicine
kit
Prior art date
Application number
BR112013025420A
Other languages
English (en)
Other versions
BR112013025420B1 (pt
Inventor
Kenji Maeda
Masafumi Toda
Tetsuro Kikuchi
Tsuyoshi Hirose
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46045045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013025420(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112013025420A2 publication Critical patent/BR112013025420A2/pt
Publication of BR112013025420B1 publication Critical patent/BR112013025420B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento a presente invenção fornece um medicamento tendo um espectro de tratamento mais amplo, que causa menos efeitos colaterais e superior em tolarabilidade e segurança, quando comparado com agentes antipsicóticos típicos conhecidos e agentes antipsicóticos atípicos. a presente invenção diz respeito a um medicamento que contenha (i) um composto que é 7-[4-(4-benzo[b]tiofen-4-il-piperazin-l-il)butóxi]-lh-quinolin-2-ona ou um sal do mesmo, e (i) pelo menos um medicamento selecionado do grupo que consiste de um estabilizador de humor, um inibidor do recaptação de norepinefrina, um inibidor da recaptação de serotonina e norepinefrina, um antidepressivo noradrenégico e serotonérgico específicos, um medicamento antiansidedade, um antidepressivo tricíclico, um antidepressivo tetracíclico, um medicamento antipsicótico e um medicamento anti-adhd, em combinação.
BR112013025420-3A 2011-04-05 2012-04-04 Medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento BR112013025420B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161471911P 2011-04-05 2011-04-05
US61/471911 2011-04-05
US201161580540P 2011-12-27 2011-12-27
US61/580540 2011-12-27
PCT/JP2012/059825 WO2012137971A1 (en) 2011-04-05 2012-04-04 Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder

Publications (2)

Publication Number Publication Date
BR112013025420A2 true BR112013025420A2 (pt) 2016-12-27
BR112013025420B1 BR112013025420B1 (pt) 2021-10-13

Family

ID=46045045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025420-3A BR112013025420B1 (pt) 2011-04-05 2012-04-04 Medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento

Country Status (31)

Country Link
US (6) US20140120185A1 (pt)
EP (4) EP4023223A1 (pt)
JP (2) JP5992924B2 (pt)
KR (1) KR101890450B1 (pt)
CN (2) CN103547260B (pt)
AR (1) AR085840A1 (pt)
AU (1) AU2012240864B2 (pt)
BR (1) BR112013025420B1 (pt)
CA (1) CA2832157C (pt)
CO (1) CO6801769A2 (pt)
CY (1) CY1120567T1 (pt)
DK (1) DK2694043T3 (pt)
EA (1) EA035837B1 (pt)
ES (1) ES2654851T3 (pt)
HK (1) HK1246159A1 (pt)
HR (1) HRP20180098T1 (pt)
HU (1) HUE035542T2 (pt)
IL (1) IL228669B (pt)
JO (2) JOP20120083B1 (pt)
LT (1) LT2694043T (pt)
MX (2) MX370670B (pt)
MY (1) MY166936A (pt)
NZ (1) NZ615591A (pt)
PL (1) PL2694043T3 (pt)
PT (1) PT2694043T (pt)
RS (1) RS56802B1 (pt)
SG (2) SG193468A1 (pt)
SI (1) SI2694043T1 (pt)
TW (1) TWI636784B (pt)
WO (1) WO2012137971A1 (pt)
ZA (1) ZA201306981B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JO3190B1 (ar) * 2011-10-19 2018-03-08 Otsuka Pharma Co Ltd محلول للتناول عن طريق الفم
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
TW201625252A (zh) 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
CA2951072A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR102452785B1 (ko) 2016-04-01 2022-10-11 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 조절 장치 및 관련 방법
EP3500249A1 (en) 2016-08-16 2019-06-26 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
KR20190075068A (ko) * 2016-10-28 2019-06-28 하. 룬드벡 아크티에셀스카브 정신 및/또는 인지 장애의 치료를 위한 이미다조피라지논을 포함하는 병용 치료
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3501506B1 (en) * 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
JP2019183095A (ja) * 2018-08-16 2019-10-24 株式会社Ｄｎｐファインケミカル 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法
JP6831354B2 (ja) * 2018-08-16 2021-02-17 株式会社Ｄｎｐファインケミカル 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法
CN113286592A (zh) * 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN113322299A (zh) * 2021-05-28 2021-08-31 南昌大学 一种抑郁症和药物成瘾疾病的药物靶点识别方法
US20240009181A1 (en) * 2022-07-08 2024-01-11 Jason Eric Schiffman Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same
FR3142667A1 (fr) * 2022-12-01 2024-06-07 Capsum Composition solide non pulvérulente comprenant au moins 8% en poids d’agent(s) désintégrant
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US20040176466A1 (en) * 2001-08-08 2004-09-09 Allen Albert John Combination therapy for the treatment of neurological disorders
BR0317771A (pt) * 2002-12-27 2005-11-22 Otsuka Pharma Co Ltd Composição farmacêutica, uso da mesma, e, método de tratar distúrbios em um paciente
AU2005259961B2 (en) * 2004-06-25 2012-05-17 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
BRPI0718318A2 (pt) * 2006-10-27 2013-11-26 Janssen Pharmaceutica Nv Processos para tratamento de distúrbios de perturbação de comportamento.
JP2008189616A (ja) * 2007-02-07 2008-08-21 Mitsubishi Tanabe Pharma Corp 注意欠陥多動性障害の治療薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物

Also Published As

Publication number Publication date
CN103547260B (zh) 2019-08-13
MY166936A (en) 2018-07-25
TWI636784B (zh) 2018-10-01
NZ615591A (en) 2016-02-26
KR101890450B1 (ko) 2018-08-21
JP2017031155A (ja) 2017-02-09
MX2013010796A (es) 2013-12-06
HRP20180098T1 (hr) 2018-03-23
JOP20120083B1 (ar) 2021-08-17
US20170100395A1 (en) 2017-04-13
WO2012137971A1 (en) 2012-10-11
CO6801769A2 (es) 2013-11-29
EP3626243A1 (en) 2020-03-25
MX2019015237A (es) 2020-02-13
EP4023223A1 (en) 2022-07-06
PT2694043T (pt) 2018-01-16
MX370670B (es) 2019-12-19
HUE035542T2 (hu) 2018-05-02
HK1246159A1 (zh) 2018-09-07
KR20140021648A (ko) 2014-02-20
RS56802B1 (sr) 2018-04-30
EA035837B1 (ru) 2020-08-19
LT2694043T (lt) 2018-02-12
DK2694043T3 (en) 2018-01-15
US20180325894A1 (en) 2018-11-15
IL228669A0 (en) 2013-12-31
US20240156811A1 (en) 2024-05-16
AU2012240864B2 (en) 2017-02-02
JP2014510023A (ja) 2014-04-24
ES2654851T3 (es) 2018-02-15
JOP20210035A1 (ar) 2023-01-30
US20220000861A1 (en) 2022-01-06
AU2012240864A1 (en) 2013-11-07
EP2694043B1 (en) 2017-11-01
ZA201306981B (en) 2014-05-28
CN108042808B (zh) 2021-02-09
CA2832157C (en) 2023-06-27
US20180042923A1 (en) 2018-02-15
CA2832157A1 (en) 2012-10-11
SG193468A1 (en) 2013-10-30
AR085840A1 (es) 2013-10-30
JP5992924B2 (ja) 2016-09-14
CN103547260A (zh) 2014-01-29
SG10201602326RA (en) 2016-04-28
IL228669B (en) 2020-04-30
BR112013025420B1 (pt) 2021-10-13
CY1120567T1 (el) 2019-07-10
PL2694043T3 (pl) 2018-04-30
TW201311242A (zh) 2013-03-16
CN108042808A (zh) 2018-05-18
EP2694043A1 (en) 2014-02-12
EP3299018A1 (en) 2018-03-28
SI2694043T1 (en) 2018-03-30
US20140120185A1 (en) 2014-05-01
EA201391450A1 (ru) 2014-03-31

Similar Documents

Publication Publication Date Title
BR112013025420A2 (pt) medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento
Ohgi et al. Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders
Martín et al. Involvement of autophagy in melatonin‐induced cytotoxicity in glioma‐initiating cells
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
Zeni et al. Antidepressant-like and neuroprotective effects of Aloysia gratissima: investigation of involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
Cosci et al. The monoamine hypothesis of depression revisited: could it mechanistically novel antidepressant strategies?
ECSP10010427A (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET
BR112014026424A2 (pt) composto, processo para produzir um composto de di-idrato, composto de benzotiofeno, método para prevenir e/ou tratar uma doença, e, composição farmacêutica
BR112012021453A2 (pt) tienopirimidina, sua composição farmacêutica e seu uso
EA201790267A1 (ru) Новые модуляторы киназ
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
CO6290695A2 (es) Uso de canabinoides en combinación con un medicamento antisicótico.
ECSP10010506A (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A.
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
BR112021020106A2 (pt) Moduladores da via de resposta ao estresse inte-grado
BR112014027884A2 (pt) combinações farmacêuticas para tratamento de distúrbios metabólicos
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
Chen et al. Antidepressant-like effect of 3-n-butylphthalide in rats exposed to chronic unpredictable mild stress: modulation of brain-derived neurotrophic factor level and mTOR activation in cortex
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2012, OBSERVADAS AS CONDICOES LEGAIS.